The Bizarre Half Price Genome at GENEDX (solved)

 A May 2026 posting by Alex Dickinson at Linked In about GeneDx reports that it is paid $2000 for genome and $4000 for exome, making the former a bad deal economically even as clinicians migrate to genome.

I think the answer is, you bill and receive $4000 for the Exome, but you bill more and have many more nonpayments for the genome.  For example, you bill Genome at $8000 and get paid one in four, presto, you have $2000.

###

https://www.linkedin.com/posts/alexgdickinson_gendx-activity-7457868325742698496-J3H7?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAC8IsMBMg_Mu0JrhdieRHyFF6Tw_rXJ3Ns

He includes a ten page AI PDF about GeneDx finances.

Here's more about that half-price genome compared to exome.

##

https://chatgpt.com/c/6a04a85d-ac40-83e8-a54e-31708ad60585

Yes — the $4,000 outpatient exome / ~$2,000 outpatient genome statement is publicly verifiable, but with an important caveat: the primary source is GeneDx management on the Q1 2026 earnings call, not an independently audited payer-by-payer table. Independent market coverage then repeated the same point.

The key passage is from GeneDx CFO Kevin Feeley on the Q1 2026 call. He said GeneDx’s blended average reimbursement rate was about $3,300, and that the shortfall was driven by product mix, not by like-for-like price cuts. He then stated that in the outpatient channel, exome was “closer to a blended average of $4,000 per test after all denials,” while outpatient genome blended ARR was “about half that of exome” because genome payer coverage is less mature. (The Motley Fool)

That matches the report’s language almost exactly: outpatient exome about $4,000 after denials and adjustments; outpatient genome about $2,000; blended ARR about $3,300, with the mix shift from exome to genome pulling realized revenue below plan.

The company’s own Q1 2026 investor deck also triangulates the math. It reports 27,488 exome/genome tests and $90.6M of exome/genome revenue, which is about $3,296 per test, i.e., GeneDx’s stated ~$3,300 Q1 ARR. The same slide says blended ARR was lower because of higher genome mix and lower parental-sample mix, while pricing and collection rates were “relatively unchanged.”

A non-company source, Investor’s Business Daily, also reported the same interpretation: outpatient WGS pricing was about $2,000, roughly half of WES, and genome had risen to about 40% of outpatient volume, creating the revenue headwind. (Investors)

Your instinct that this looks odd against public fee schedules is right. Public schedules do not generally show genome at half of exome. For example, Maryland’s 2026 Medicaid lab schedule lists 81415 exome at $3,800.10, 81416 comparator at $954, 81425 genome at $3,999.80, and 81426 comparator genome at $2,154.40 — genome is not lower than exome there. (Maryland.gov Enterprise Agency Template) Children’s Hospital Colorado’s 2026 laboratory fee schedule similarly lists exome proband at $2,550, exome trio at $4,386, genome proband at $3,774, and genome trio at $5,610.

So the reconciliation is: GeneDx is not saying the fee schedule for genome is $2,000. It is saying its realized outpatient blended ARR for genome is about $2,000 after coverage gaps, denials, adjustments, payer mix, and likely zero-pay cases. That is a very different number from Medicare CLFS, Medicaid fee schedules, hospital chargemasters, or allowed amounts when a claim is cleanly covered. CMS itself describes CLFS rates as weighted medians of private-payer rates for the test, which is still not the same thing as a company’s net realized revenue across all submitted outpatient claims. (Centers for Medicare & Medicaid Services)

Bottom line: the report’s statement is real and traceable to GeneDx’s Q1 2026 call, and it is repeated by independent financial coverage. But I would phrase it carefully:

“GeneDx management stated that, in its outpatient channel, realized ARR for exome is about $4,000 after denials, while outpatient genome ARR is roughly half that level, or about $2,000, reflecting immature payer coverage rather than the nominal public fee schedule value of CPT 81425.”

###

yes, it starts as a puzzle but becomes trivial. bill $8000 for genome, get paid one in four, and that's your $2000. E-Z.

Exactly. The headline fee schedule comparison makes it look bizarre: “How can genome be worth half of exome?” But the operating math is not really price; it is realized yield per ordered test.

So the structure is more like:

Nominal allowed / billed / expected value: genome may look comparable to or higher than exome.
Coverage reality: many outpatient genome claims are not covered, denied, appealed, delayed, or written off.
Realized ARR: if the effective collection rate is much worse, the average collapses.

So your example is the right intuition:

Bill/allow/expect $8,000 for genome × 25% realized collection = $2,000 realized ARR.

Meanwhile, outpatient exome may have a decade of coverage-policy muscle memory behind it, so perhaps the exome claim is less exotic to payers, better covered, better preauthorized, and less often zero-paid. Thus:

Exome may not be “priced higher” than genome. It may simply be paid more often.

That also explains why the GeneDx issue is financially ugly but not scientifically mysterious. The company’s customers are migrating toward the biologically broader test, but the payer system is still treating outpatient genome as a less settled coverage category. So the clinical adoption curve and the revenue curve temporarily move in opposite directions.

A concise way to say it:

The GeneDx surprise was not that genome has a lower fee schedule value than exome. It was that outpatient genome has a lower realized cash yield because coverage is immature. In practice, a high nominal genome price multiplied by a weak collection rate can easily land at half the realized revenue of exome.